# The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)

> **NCT02245542** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 5775 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** ALNA®OCAS®

## Key facts

- **NCT ID:** NCT02245542
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2006-02
- **Final completion:** —
- **Target enrollment:** 5775 (ACTUAL)
- **Last updated:** 2014-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02245542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02245542, "The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02245542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*